Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00120250 · ClinicalTrials.gov registry record · Phase 4
Eszopiclone for Sleep Disturbance and Nightmares in Post-Traumatic Stress Disorder
A Phase 4 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 4
- Development phase
- 27
- Enrollment target
NCT00120250: Completed Phase 4 study, sponsored by Massachusetts General Hospital.
NCT00120250 is a Phase 4 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 27 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00120250, a Phase 4 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 27 participants
- Enrollment target
Study Summary
The purpose of this study is to obtain data investigating the safety and efficacy of eszopiclone for the treatment of post-traumatic stress disorder (PTSD)-related sleep disturbance and the impact of improved sleep with eszopiclone treatment on neuroendocrine correlates of PTSD. The investigators hypothesize that eszopiclone will be significantly more effective than placebo and well tolerated for PTSD-related sleep disturbance, improvement in sleep will be associated with improvement in overall PTSD symptoms, and patients with PTSD-related sleep disturbances will have abnormal levels of stress hormones.
Interventions
- DRUG Eszopiclone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2005-06 |
| Est. Completion | 2008-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00120250
The ClinicalTrials.gov registry entry for NCT00120250 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Eszopiclone is the first listed.
NCT00120250 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00120250 about?
NCT00120250 is a clinical study titled "Eszopiclone for Sleep Disturbance and Nightmares in Post-Traumatic Stress Disorder". The purpose of this study is to obtain data investigating the safety and efficacy of eszopiclone for the treatment of post-traumatic stress disorder (PTSD)-related sleep disturbance and the impact of improved sleep with eszopiclone treatment on neuroendocrine correlates of PTSD. The investigators hy...
What is the current status of trial NCT00120250?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 27 participants. The study started on 2005-06. Estimated completion is 2008-06.
What interventions are being tested in trial NCT00120250?
The interventions under investigation include: Eszopiclone (DRUG).
Who is sponsoring clinical trial NCT00120250?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.